Explore
Biosimilars in Europe
0 Ungluers have
Faved this Work
Login to Fave
This reprint examines regulatory, pricing and reimbursement issues related to the market access and uptake of off-patent biologics, biosimilars, next-generation biologics and competing innovative medicines in European countries.
This book is included in DOAB.
Why read this book? Have your say.
You must be logged in to comment.
Rights Information
Are you the author or publisher of this work? If so, you can claim it as yours by registering as an Unglue.it rights holder.Downloads
This work has been downloaded 92 times via unglue.it ebook links.
- 92 - pdf (CC BY) at Unglue.it.
Keywords
- adalimumab
- approval
- award criteria
- Barriers
- Belgium
- biological
- biologics
- biosimilar
- biosimilar market
- biosimilar sustainability
- biosimilar/supply and distribution
- biosimilarity assessment
- biosimilars
- budget impact analysis
- clinical
- clinical governance
- Communication
- Competition
- competitive market
- cost containment
- cost simulation
- Delphi technique
- drug costs
- Economics, finance, business & management
- Education
- etanercept
- Europe
- European public assessment reports (EPARs)
- Germany
- healthcare costs
- HER2-positive breast cancer
- incentives
- Industry & industrial studies
- infliximab
- information
- interchangeability
- Intravenous
- Manufacturing industries
- market dynamics
- medicine
- n/a
- off-patent
- Patient
- Pharmaceutical industries
- pharmaceutical spending
- Policies
- potentially critical quality attributes (pCQAs)
- Pricing
- Procurement
- quality attributes (QAs)
- queries
- reference biological
- Regulatory
- regulatory science
- reimbursement
- review
- savings
- Spain
- subcutaneous
- sustainability
- switching
- tender
- TNFα inhibitors
- trastuzumab
- uptake
- Utilization
Links
DOI: 10.3390/books978-3-0365-6574-3Editions